title: Role of pyruvate dehydrogenase inhibition in the development of hypertrophy in the hyperthyroid rat heart: a combined magnetic resonance imaging and hyperpolarized magnetic resonance spectroscopy study.
abstract: BACKGROUND
  Hyperthyroidism increases heart rate, contractility, cardiac output, and metabolic rate. It is also accompanied by alterations in the regulation of cardiac substrate use. Specifically, hyperthyroidism increases the ex vivo activity of pyruvate dehydrogenase kinase, thereby inhibiting glucose oxidation via pyruvate dehydrogenase. Cardiac hypertrophy is another effect of hyperthyroidism, with an increase in the abundance of mitochondria. Although the hypertrophy is initially beneficial, it can eventually lead to heart failure. The aim of this study was to use hyperpolarized magnetic resonance spectroscopy to investigate the rate and regulation of in vivo pyruvate dehydrogenase flux in the hyperthyroid heart and to establish whether modulation of flux through pyruvate dehydrogenase would alter cardiac hypertrophy.
  
  
  RESULTS
  Hyperthyroidism was induced in 18 male Wistar rats with 7 daily intraperitoneal injections of freshly prepared triiodothyronine (0.2 mg x kg(-1) x d(-1)). In vivo pyruvate dehydrogenase flux, assessed with hyperpolarized magnetic resonance spectroscopy, was reduced by 59% in hyperthyroid animals (0.0022 ± 0.0002 versus 0.0055 ± 0.0005 second(-1); P=0.0003), and this reduction was completely reversed by both short- and long-term delivery of dichloroacetic acid, a pyruvate dehydrogenase kinase inhibitor. Hyperpolarized [2-(13)C]pyruvate was also used to evaluate Krebs cycle metabolism and demonstrated a unique marker of anaplerosis, the level of which was significantly increased in the hyperthyroid heart. Cine magnetic resonance imaging showed that long-term dichloroacetic acid treatment significantly reduced the hypertrophy observed in hyperthyroid animals (100 ± 20 versus 200 ± 30 mg; P=0.04) despite no change in the increase observed in cardiac output.
  
  
  CONCLUSIONS
  This work has demonstrated that inhibition of glucose oxidation in the hyperthyroid heart in vivo is mediated by pyruvate dehydrogenase kinase. Relieving this inhibition can increase the metabolic flexibility of the hyperthyroid heart and reduce the level of hypertrophy that develops while maintaining the increased cardiac output required to meet the higher systemic metabolic demand.
authors: Department of Biochemistry, Sanger Bldg, University of Cambridge, Tennis Court Rd, Cambridge CB2 1GA, UK. hja24@cam.ac.uk
authors: Helen J
authors: HJ
authors: Atherton
authors: Michael S
authors: MS
authors: Dodd
authors: Lisa C
authors: LC
authors: Heather
authors: Marie A
authors: MA
authors: Schroeder
authors: Julian L
authors: JL
authors: Griffin
authors: George K
authors: GK
authors: Radda
authors: Kieran
authors: K
authors: Clarke
authors: Damian J
authors: DJ
authors: Tyler
references: Biochem J. 1974 Sep;141(3):761-74
references: 4478069
references: Circ Res. 2009 Mar 27;104(6):805-12
references: 19213957
references: J Cardiovasc Magn Reson. 2006;8(2):327-33
references: 16669175
references: Endocr Rev. 2010 Oct;31(5):663-79
references: 20519325
references: Biochem J. 2000 Dec 15;352 Pt 3:731-8
references: 11104680
references: Toxicol Lett. 2004 Feb 2;146(3):197-205
references: 14687757
references: Circ Res. 2001 Sep 28;89(7):557-9
references: 11577018
references: J Neuropathol Exp Neurol. 2009 Sep;68(9):985-93
references: 19680144
references: Adv Myocardiol. 1985;6:299-309
references: 2986261
references: Am J Physiol. 1985 Mar;248(3 Pt 1):C309-19
references: 3156508
references: J Mol Cell Cardiol. 1997 Oct;29(10):2771-8
references: 9344771
references: J Biol Chem. 1979 Oct 10;254(19):9492-9
references: 489548
references: J Mol Cell Cardiol. 1995 Mar;27(3):901-8
references: 7602608
references: Muscle Nerve. 2001 Jul;24(7):916-24
references: 11410919
references: FEBS Lett. 1997 Dec 8;419(1):55-7
references: 9426219
references: Physiol Genomics. 2006 Oct 11;27(2):178-86
references: 16868074
references: Nature. 1975 Oct 30;257(5529):808-9
references: 171583
references: FASEB J. 1990 Nov;4(14):3224-33
references: 2227213
references: Am J Physiol. 1997 Jul;273(1 Pt 1):E139-48
references: 9252490
references: J Clin Invest. 1987 Feb;79(2):588-94
references: 3543056
references: Physiol Genomics. 2007 Apr 24;29(2):99-108
references: 17190852
references: Thyroid. 2002 Jun;12(6):447-52
references: 12165105
references: Biochem J. 1992 Sep 1;286 ( Pt 2):513-7
references: 1530584
references: J Biol Chem. 2010 Jan 22;285(4):2375-85
references: 19948729
references: Biochem J. 1973 Jun;134(2):651-3
references: 16742828
references: J Magn Reson. 2010 Jan;202(1):85-92
references: 19884027
references: Biochem J. 1976 Feb 15;154(2):327-48
references: 180974
references: FASEB J. 2009 Aug;23(8):2529-38
references: 19329759
references: J Cardiometab Syndr. 2007 Summer;2(3):198-206
references: 17786084
references: J Clin Endocrinol Metab. 2002 Oct;87(10):4747-53
references: 12364469
references: Biochem J. 1998 Jan 1;329 ( Pt 1):191-6
references: 9405293
references: Horm Metab Res. 1999 May;31(5):300-6
references: 10422724
references: Endocrinology. 2010 Jan;151(1):422-31
references: 19940039
references: Endocrinology. 2007 Mar;148(3):1206-17
references: 17122078
references: Am J Physiol Endocrinol Metab. 2001 Oct;281(4):E848-56
references: 11551863
references: FEBS Lett. 1993 Dec 28;336(3):501-5
references: 8282119
references: Biochem Soc Trans. 2001 May;29(Pt 2):272-8
references: 11356166
references: Am J Physiol. 1998 Aug;275(2):E235-42
references: 9688624
references: Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10158-63
references: 12930897
references: Circ Res. 1979 Jan;44(1):1-7
references: 152679
references: J Biol Chem. 1998 May 15;273(20):12187-94
references: 9575166
references: Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19773-7
references: 18056642
references: Biochem Soc Trans. 1986 Oct;14(5):799-806
references: 3536635
references: Biochem J. 1990 Oct 15;271(2):421-5
references: 2241923
references: Mol Cell. 1999 Oct;4(4):597-609
references: 10549291
references: FEBS Lett. 2006 Jul 24;580(17):4282-7
references: 16831433
references: NMR Biomed. 2011 Feb;24(2):201-208
references: 20799252
references: J Clin Invest. 1967 Oct;46(10):1669-82
references: 6061742
references: Analyst. 1998 Dec;123(12):2653-60
references: 10435319
references: Biochem J. 2002 Jun 15;364(Pt 3):687-94
references: 12049632